Oxygen Biotherapeutics (OXBT) leaps 19% premarket.
The company says aggregated results from 14 clinical trials show "levosimendan was associated with reduced mortality and other adverse outcomes including heart attacks during and after operation in patients with reduced heart function undergoing heart surgery."
The findings were published in the Journal of Cardiothoracic and Vascular Anesthesia. (PR)
OXBT is set to acquire the U.S. commercialization and development rights to levosimendan from privately held Phyxius Pharma. More on this deal here.